Stock Watch: Advanced Therapies Deliver Fourth-Quarter Flop
Despite Obvious Clinical Benefits, Successful Commercialization Remains Elusive
As drug pricing continues its ascent among hot button issues, the multi-million-dollar price tags for one-and-done advanced therapies, their justification and reimbursement all remain unaligned.
